Andrea Lobo, PhD,  —

Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.

Articles by Andrea Lobo

FDA approves Bkemv, first Soliris biosimilar, to treat PNH

The U.S. Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb), the first interchangeable biosimilar of Soliris (eculizumab), to treat people with paroxysmal nocturnal hemoglobinuria (PNH). Soliris is an intravenous (into-the-vein) antibody-based therapy that is approved to reduce hemolysis, or red blood cell destruction, in PNH patients. As…

Acute hemolysis in PNH managed with intensive Empaveli dosing

An intensive dosing regimen of Empaveli (pegcetacoplan) effectively managed events of acute red blood cell destruction, called hemolysis, in people with paroxysmal nocturnal hemoglobinuria (PNH), according to an ongoing clinical study’s interim data. Also, the intensive regimen was found to be safe and well tolerated in these patients,…

Free app designed to help PNH patients with disease management

Dawn Health, a Danish digital health company, and Novartis have launched a smartphone app designed to help people living with paroxysmal nocturnal hemoglobinuria (PNH) with disease management. The free Ekiva PNH app helps patients track their symptoms and prepare for medical appointments, while also providing a…

NM5072, for anemia in PNH patients, named orphan drug in US

The U.S. Food and Drug Administration (FDA) has given orphan drug designation to NM5072, an experimental treatment for anemia in people with paroxysmal nocturnal hemoglobinuria (PNH). The potential therapy showed safety and tolerability in an initial clinical trial in healthy volunteers, and a Phase 2 trial in PNH patients…

NovelMed’s PNH antibody therapy NM8074 now called ruxoprubart

NM8074, an investigational antibody therapy for paroxysmal nocturnal hemoglobinuria (PNH), will now be called ruxoprubart, its developer NovelMed has announced. The name change came after the USAN, or United States Adopted Names Council, selected ruxoprubart as the unique generic, or nonproprietary, name for the therapy candidate. According to…

Empaveli seen to ease fatigue, boost blood oxygen in real-world study

Treatment with Empaveli (pegcetacoplan) — a C3 protein blocker — effectively improved disease control and health-related quality of life, while reducing fatigue in people with paroxysmal nocturnal hemoglobinuria (PNH) in the U.S. and Europe, a real-world study reported. Study findings also showed higher physician and patient satisfaction with…